McMaster University

McMaster University

Matthew J. McQueen

, MBChB, PhD, FCACB, FRCPC

Professor Emeritus (2014)
Pathology and Molecular Medicine

Division: Clinical Pathology

mcquemat@hhsc.ca

Matthew J. McQueen

Faculty Biography

Education and Professional Standing

  • FCACB, 1984
  • FRCPC, 1981
  • PhD, University of Glasgow, Scotland, 1972
  • MBChB, University of Glasgow, Scotland, 1968

Interests

Research Focus

Cardiovascular disease with particular emphasis on lipids, lipoproteins and apolipoproteins, as well as the role of biomarkers in the prediction, diagnosis and management of myocardial ischemia.

Clinical Focus

The use of lifestyle and pharmacological interventions in the prevention and management of cardiovascular disease. 

Academic Interests

The role of large international clinical and epidemiological studies in contributing to greater understanding of factors influencing population health, in combination with the development and maintenance of a large biobank to support such studies.  These activities and interests are facilitated through the Population Health Research initiative at the David Braley Cardiac Vascular and Stroke Research Institute.


Team Members

Clinical Trials/Proteomics Laboratory Team

  • Dr. Joseph Macri: Clinical Biochemist (Lab Medicine), Associate Professor (Pathology & Molecular Medicine)
  • Dr. Judy Keys: Research Coordinator
  • Kim Hall: Research Coordinator, Clinical Research and Clinical Trials

Selected Publications

  • M.J. McQueen, A. Sniderman.  Commentary on ‘Either Cholesterol or Apolipoprotein Levels Can Be Used to Determine Risk For CVD; Triglycerides Are Not Useful’. ACP Journal Club 2010; 152: JC2-12.
  • Sniderman AD, Williams K, McQueen MJ, Furberg CD.  When is Equal Not Equal?  J. Clin Lipidol 2010; 4:83-88.
  • Sniderman A, McQueen M., Contois J, Williams K, Furberg CD.  Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol.  J Clin Lipidol 2010; 4: 152-155.
  • Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Rangarajan S, Gerstein HC, Anand SS for the INTERHEART Investigators.  Metabolic Syndrome and Risk of Acute Myocardial Infarction:  A case-control study in 26,903 subjects from 52 countries.  J Am Coll Cardiol 2010; 21: 2390-2398.
  • O’Donnell M, Xavier D, Lisheng L, Zhang H. Chin SL, Rao-Melacini P, Rangarajan S, Isham S, Pais P, McQueen M, Mondo C, Domascero A, Lopez-Jaramillo P, Hankey GJ, Dans T, Yusoff K, Truelsen T, Diener HC, Ryglewicz D, Czlonkowska A, Weimar C, Yusuf S.  On behalf of the INTERSTROKE investigators. Risk factors for ischaemic and haemorrhagic stroke in 22 countries. Results of the first phase of INTERSTROKE in 6000 individuals.  Lancet 2010; 376: 112-123.
  • Anand SS, Xie C, Paré G, Monpetit A, Serre D, Rangarajan S, McQueen MJ, Cordell H, Kearney B, Yusuf S, Hudson TJ, Engert JC, on behalf of the INTERHEART Investigators. Genetic Variants Associated with Acute Myocardial Infarction risk factors in over 8,000 Individuals from Five Ethnic Groups:  The INTERHEART Genetics Study.  Circ Cardiovasc Genet 2009; 2: 16-25. 
  • Hill S, Cleve R, Carlisle E, Robinson K, Wickenden T, Young E, McQueen M.  Intra-Individual variability in Troponin T concentration in dialysis patients.  Clin Biochem 2009; 42: 991-995.
  • Mann JFE, Sheridan P, McQueen MJ, Held C, Arnold M, Fodor G, Yusuf S, Lonn EM on behalf of the HOPE 2 Investigators.  Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease:  Results of the renal HOPE 2 Study.   Nephrol Dial Transplant, 2008; 23: 645-653.
  • McQueen MJ. Evidence for the use of urinary albumin as a marker of kidney involvement in unselected populations.  Scand J Clin Lab Invest 2008; 68, S241: 52-56.
  • McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazimi K, Yusuf S, for the INTERHEART study investigators.  Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.  Lancet 2008; 372: 224-33.
  • Mann JFE, Schmilder RE, McQueen M, Dyal L, Schumacker H. Pogue J, Wang X, Maggioni A, Budaj J et al, on behalf of the ONTARGET investigators.  Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk: results from a multicentre, randomized, double-blind, controlled trial.  Lancet 2008; 372: 547-53.
  • Al-Harbi TM, Bainbridge LJ, McQueen MJ, Tarnopolsky MA.  Hypogonadism is common in men with myopathies.  J. Clin Neuromusc Dis 2008; 9: 397-401.
  • Held C, Sumner G, Sheridan P, McQueen M, Smith S, Dagenais G, Yusuf S, Lonn E.  Correlations between plasma homocysteine concentrations and carotid atherosclerosis in high-risk individuals.  The Homocysteine and Atherosclerosis Reduction Trial (HART).   Vascular Medicine, 2008; 13: 245-253.
  • Dagenais G, Gerstein HC, Holman RR, Budaj A, Escalante T, Hedner M, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S.  For the DREAM Trial Investigators.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People with Impaired Glucose Tolerance or Impaired Fasting Glucose.  Results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Trial.  Diabetes Care, 2008; 31: 1007-1014.
  • McQueen MJ, Don-Wauchope AC.  Requesting and Interpreting Urine Albumin Measurements in the Primary Health Care Setting.  Editorial. Clin Chem 2008; 54: 1595-1597.
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0